Literature DB >> 10465067

The CDK9-associated cyclins T1 and T2 exert opposite effects on HIV-1 Tat activity.

G Napolitano1, P Licciardo, P Gallo, B Majello, A Giordano, L Lania.   

Abstract

OBJECTIVES: To examine the functional interaction between HIV-1 Tat protein and the cyclin T1 and T2 proteins which, in association with cyclin dependent kinase (CDK)9, are the regulatory subunits of the TAK/P-TEFb cellular complex strictly required for Tat transactivation.
DESIGN: HIV-1 long terminal repeat (LTR) reporter plasmid was co-transfected into human and rodent cells with expression vectors encoding Tat and vectors encoding the cyclins T1, T2a and T2b, respectively.
METHODS: Tat-mediated transactivation of HIV-1 LTR-driven transcription was compared in the presence or absence of different cyclins T (T1, T2a and T2b), upon co-transfections into human and rodent cell lines. Protein interactions were analysed by in vitro binding assays.
RESULTS: It was found that Tat function in rodent cells is enhanced by co-expression of cyclin T1 but not cyclin T2. The N-terminal region (amino acids 1-290) of cyclin T1 is sufficient for this function and for binding to Tat and CDK9. Cyclin T2 binds to CDK9 but not to Tat. Moreover, enforced expression of cyclin T2 inhibits cyclin T1-mediated enhancement of Tat in rodent cells and it represses Tat activity in human cells.
CONCLUSION: Efficient Tat transactivation in rodent cells occurs in the presence of human cyclin T1 but not in the presence of cyclin T2; overexpression of cyclin T2 inhibits Tat function in both rodent and human cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10465067     DOI: 10.1097/00002030-199908200-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

Review 1.  P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.

Authors:  D H Price
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 2.  Comparative pathogenesis of epsilonretroviruses.

Authors:  Donald Holzschu; Lorie A Lapierre; Michael D Lairmore
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

3.  Antiapoptotic function of Cdk9 (TAK/P-TEFb) in U937 promonocytic cells.

Authors:  S M Foskett; R Ghose; D N Tang; D E Lewis; A P Rice
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Downregulation of microRNA-142-3p and its tumor suppressor role in gastric cancer.

Authors:  Yi Wang; Zhidong Cao; Lanlan Wang; Siqi Liu; Jianqiang Cai
Journal:  Oncol Lett       Date:  2018-03-23       Impact factor: 2.967

5.  Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines.

Authors:  R Ghose; L Y Liou; C H Herrmann; A P Rice
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Cyclin T1 expression is mediated by a complex and constitutively active promoter and does not limit human immunodeficiency virus type 1 Tat function in unstimulated primary lymphocytes.

Authors:  Juan Martin-Serrano; Kelvin Li; Paul D Bieniasz
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Progranulin (granulin/epithelin precursor) and its constituent granulin repeats repress transcription from cellular promoters.

Authors:  Mainul Hoque; Michael B Mathews; Tsafi Pe'ery
Journal:  J Cell Physiol       Date:  2010-04       Impact factor: 6.384

8.  Cdk9 phosphorylates Pirh2 protein and prevents degradation of p53 protein.

Authors:  Asen Bagashev; Shongshan Fan; Ruma Mukerjee; Pier Paolo Claudio; Tinatin Chabrashvili; Roger P Leng; Samuel Benchimol; Bassel E Sawaya
Journal:  Cell Cycle       Date:  2013-04-19       Impact factor: 4.534

9.  CDK9/cyclin complexes modulate endoderm induction by direct interaction with Mix.3/mixer.

Authors:  Haiqing Zhu; Joanne R Doherty; Emin Kuliyev; Paul E Mead
Journal:  Dev Dyn       Date:  2009-06       Impact factor: 3.780

10.  Inhibition of HIV-1 transcription and replication by a newly identified cyclin T1 splice variant.

Authors:  Guozhen Gao; Xiaoyun Wu; Jieqiong Zhou; Mingfeng He; Johnny J He; Deyin Guo
Journal:  J Biol Chem       Date:  2013-04-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.